J&J’s Spravato Bests Quetiapine in Phase III Head-to-Head Depression Study

Johnson & Johnson’s nasal spray Spravato (esketamine) CIII outperformed extended-release quetiapine at inducing remission in patients with treatment-resistant depression, the company announced Wednesday at the same time the results were published in The New England Journal of Medicine.